Our Shareholders

• Focused strategy for Africa with distribution capabilities in key African economies (21Countries).
• Ability to grow in a highly volatile emerging market.
• Innovative and goal driven Healthcare company (Pharma, Disposables, Devices and Ortho):
• Over 9,000 products
• 25 years of experience
• 800 employees
• 35 regulatory pharmacists
• 9 health care production facilities
• US$160 million annual turnover
• Accessing high value dossiers (Proprietary IP) from across the globe building and sustaining long term partnerships
• Click here to visit their website

• Established: 1940
• Type of organisation: Development Finance Institution (DFI)
• Ownership: 100% owned by South African Government
• Total assets: USD 9.6 billion (31 March 2017 – group)
• Total liabilities: USD 3.1 billion (31 March 2017 – group)
• Funding status: Fund operations and growth from investments, pay dividends & income tax
• Credit rating: Baa3 (Moody’s)
• Main business area: Providing funding for big business, entrepreneurs and projects contributing to industrialization
• Geographic activities: South Africa and the rest of Africa
• Stage of investment: Project identification and development, feasibility, commercialization, expansion, modernization
• No. of employees: 839 (March 2017)
• Operational footprint: Head Office in Johannesburg & 20 Regional and Satellite offices
• Click here to visit their website

Afrigen’s Board of Directors

• Non-Executive Directors

  1. Dr Vikramkumar Naik (Chairperson),
  2. Dr Tadesse Teferi Mekonen (Ethiopian),
  3. Dr Ntuthuko Melusi Bhengu,
  4. Mr Mehmet Levent  Selamoglu (UK),
  5. Dr Vathiswa Belinda Papu-Zamxaka,
  6. Mr Shawn Renders                                                                       

   

  Executive Directors

  1. Prof Aletta Petronella Susarah Terblanche (Managing Director); and
  2. Dr Carryn Janine Fenner (Executive Director: mRNA Hub).